Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.42 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.80 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    -2.04 (-2.60%)
     
  • Gold

    2,045.80
    +15.10 (+0.74%)
     
  • Silver

    22.98
    +0.19 (+0.84%)
     
  • EUR/USD

    1.0823
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2673
    +0.0015 (+0.12%)
     
  • USD/JPY

    150.4400
    -0.0600 (-0.04%)
     
  • Bitcoin USD

    51,631.63
    +773.54 (+1.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

Repare Therapeutics Inc. RPTX is using its genome-wide, CRISPR-enabled SNIPRx platform to discover and develop highly targeted cancer therapies that cater to genomic instability, including DNA damage repair.

The company currently has two candidates in its clinical pipeline, camonsertib, an ATR inhibitor and lunresertib, a PKMYT1 Inhibitor. These two candidates are currently undergoing early-mid-stage development in various cancer indications.

Last week, Repare announced that two additional candidates, RP-1664 and RP-3467, are likely to enter early-stage clinical development in 2024. Following the news, shares of the company have surged 34.2% in the past week compared with the industry’s 1.7% rise.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

RP-1664 is the company’s investigational oral PLK4 inhibitor, which is being developed as a potential treatment for various solid tumor indications. Per the company, RP-1664 has demonstrated robust and dose-dependent monotherapy efficacy across a variety of tumor types, including breast cancer, non-small cell lung cancer and neuroblastoma, in pre-clinical studies.

RPTX anticipates initiating a phase I dose-escalation study of RP-1664 in adult and adolescent patients with TRIM37-high solid tumors in the first half of 2024.

RP-3467, on the other hand, is Repare’s investigational Polθ inhibitor. RP-3467’s mechanism of action holds similarity with PARP inhibitor activity, whereby, the former has shown durable and complete tumor regressions in multiple preclinical studies when administered as a monotherapy.

Pre-clinical study data has also demonstrated RP-3467’s potential to be developed in combination with radioligand therapy, antibody-drug conjugates and multiple chemotherapies.

Repare expects to begin a phase I dose-finding study of RP-3467 in the second half of 2024.

The RP-1664 and RP-3467 programs represent the company’s third and fourth internally developed clinical candidates after camonsertib and lunresertib.

Repare Therapeutics Inc. Price and Consensus

Repare Therapeutics Inc. Price and Consensus
Repare Therapeutics Inc. Price and Consensus

Repare Therapeutics Inc. price-consensus-chart | Repare Therapeutics Inc. Quote

Zacks Rank and Stocks to Consider

Repare currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Agenus AGEN. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and AGEN carry a Zacks Rank #2 (Buy) each at present.

You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 30 days, the Zacks Consensus Estimate for Ligand’s 2023 earnings per share has remained constant at $5.10. During the same time frame, the estimate for Ligand’s 2024 earnings per share has remained constant at $4.59. In the past week, shares of LGND have gained 4.8%.

LGND’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.19%.

In the past 30 days, the Zacks Consensus Estimate for Acadia’s 2023 loss per share has narrowed from 37 cents to 34 cents. The estimate for Acadia’s 2024 earnings per share is pegged at 90 cents. In the past week, shares of ACAD have inched up 1.9%.

ACAD beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average earnings surprise of 20.69%.

In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has narrowed from 77 cents to 63 cents. During the same time frame, the estimate for Agenus’ 2024 loss per share has narrowed from 70 cents to 45 cents. In the past week, shares of AGEN have gained 9.9%.

AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report

Agenus Inc. (AGEN) : Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report

Repare Therapeutics Inc. (RPTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement